Akin R, Okutan V, Sarici U, Altunbas A, Gökçay E
Department of Pediatrics, Gülhane Military Medical Academy, Ankara, Turkey.
Pediatr Neurol. 1998 Aug;19(2):129-31. doi: 10.1016/s0887-8994(98)00039-3.
The effects of the valproic acid and carbamazepine monotherapies on bone mineral density were evaluated. Bone mineral density was measured in 53 children with primary epilepsy taking either valproic acid (n = 25) or carbamazepine (n = 28) for longer than 1 year and in a healthy control group (n = 26) by the dual-energy x-ray absorptiometry method at L2-L4 levels of lumbar vertebrae. The mean serum levels of valproic acid and carbamazepine were 66 +/- 2.2 microg/mL and 7.0 +/- 9.3 microg/mL, respectively, and the mean duration of treatment for each drug was 2.4 +/- 0.2 years and 2.6 +/- 0.5 years, respectively. Calcium intakes in diet were similar in both the control and study groups. The serum levels of calcium and phosphorus in all groups were normal. Bone mineral density values of both valproic acid and carbamazepine groups were not statistically different from that of the control group (P > 0.05).
评估了丙戊酸和卡马西平单一疗法对骨密度的影响。采用双能X线吸收法，在L2-L4腰椎水平对53例服用丙戊酸（n = 25）或卡马西平（n = 28）超过1年的原发性癫痫患儿以及一个健康对照组（n = 26）进行骨密度测量。丙戊酸和卡马西平的平均血清水平分别为66±2.2μg/mL和7.0±9.3μg/mL，每种药物的平均治疗时长分别为2.4±0.2年和2.6±0.5年。对照组和研究组的饮食钙摄入量相似。所有组的血清钙和磷水平均正常。丙戊酸组和卡马西平组的骨密度值与对照组相比无统计学差异（P>0.05）。
